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Abstract
Background: Viral hepatitis and sexually transmitted infections (STIs) are key public health problems that pose an
enormous risk for disease transmission in the general population. This study estimated, for the first time, prevalence
estimates of serologic markers of HCV, HBV, HAV, HIV and HSV-2 in the adult population of Puerto Rico and
assessed variations across sociodemographic and behavioral characteristics.
Methods: A seroepidemiologic survey was employed using a stratified cluster probability sample of households in
Puerto Rico. Participants completed a face-to-face interview, a self-administered questionnaire using an ACASI
system, and provided blood specimens for antibody testing. Prevalence estimates of viral hepatitis, HIV and HSV-2
were estimated using a logistic regression model weighting for the probability of participation in each household
block and the inverse of the probability of selection according to geographic strata, households’ blocks, and sex
distribution.
Results: A total of 1,654 adults participated in the study. Seroprevalence estimates for HCV (2.3%, 95% CI: 1.3%-
4.2%), HBV (3.1%, 95% CI: 2.0%-4.7%), and HSV-2 (22.3%, 95% CI: 18.5%-26.7%) in Puerto Rico are roughly in
agreement with estimates obtained in the US population; however, HAV (41.3%, 95% CI: 36.9%-45.8%) and HIV
(1.1%, 95% CI: 0.5%-2.3%) seroprevalence estimates in Puerto Rico were higher. The proportion of individuals that
were unaware of their serostatus was as follows: 80% for HCV, 98.3% for HBV, 96.4% for HAV, 36.4% for HIV, and
97.8% for HSV-2. Post-stratification estimates of seroprevalence varied significantly by demographic and risk related
characteristics.
Conclusion: This data underscore the disproportionate impact of some viral infections across selected population
subgroups in Puerto Rico. A concerted island-wide effort is needed to strengthen viral hepatitis and STIs
prevention and control strategies, support surveillance to monitor chronic infections, and ensure appropriate
counseling, testing, and medical management of infected persons. Integration of HCV, HBV, and HSV-2 counseling
into HIV existing prevention services and outreach through social networks might represent a valuable approach to
reach high-risk individuals.
Background
Viral hepatitis and sexually transmitted infections (STIs)
are key public health threats that pose an enormous risk
for disease transmission in the general population.
Chronic infections with hepatitis B virus (HBV) and
hepatitis C virus (HCV) are a leading cause of
hepatocellular carcinoma, a condition whose incidence
rate remains high in the developing world and is rising
across most developed countries [1]. In 2007, the Cen-
ters for Disease Control and Prevention estimated that
85,000 new acute viral hepatitis cases and nearly 19 mil-
lion new STIs occurred in the United States (US) [2,3].
In addition to the physical and psychological conse-
quences of these diseases, the economic impact of STIs
and of the viral hepatitis in the US are conservatively
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lars, and $1.8 billion, based on 1999 dollars, respectively
[4,5]. Taking into account that these statistics do not
reflect the true burden of viral hepatitis caused by
chronic infection with HBV and HCV, that many cases
of notifiable acute hepatitis and STIs are undiagnosed,
and some common viral infections, such as genital
herpes and human papillomavirus infection, are not
notifiable infectious diseases in the US, the true burden
of viral hepatitis and STIs is underestimated [2,3,5,6].
Viral hepatitis and STIs share similar at-risk popula-
tions and risk factors. For example, those who are
infected with certain STIs have a three to five-fold
increased risk for HIV infection, 33% of all HIV-infected
persons are HCV infected, and 5-15% of HIV-infected
persons are co-infected with HBV [7,8]. These diseases
also share similar social determinants, including poor
access to health care, stigma, discrimination, homopho-
bia, and poverty [5,6].
The National Health and Nutrition Examination Sur-
vey (NHANES) has provided reliable estimates of viral
hepatitis (HCV, HBV, and hepatitis A virus (HAV)) and
STIs including HIV and herpes simplex virus type 2
(HSV-2) across various racial and ethnic groups in the
US [9-14]. However, Puerto Rico, as a jurisdiction, is
excluded from NHANES. Accurate estimates for the
impact of these viral infections in this Hispanic sub-
group are important for predicting future trends and
directing preventive efforts. Although the HIV/AIDS
epidemic has disproportionately affected Puerto Ricans,
with estimated rates per 100,000 population of 223.0 for
HIV and 354.7 for AIDS during 2007, population-based
surveys on viral hepatitis and STIs in Puerto Rico are
scant [15-17]. Information on the burden of HIV and
other STIs in Puerto Rico has relied upon surveillance
systems or respondents’ self-reports of symptoms and
diagnoses provided in the Behavioral Risk Factor Sur-
veillance Survey (BRFSS). Meanwhile, epidemiologic
data regarding the burden of viral hepatitis and related
complications are limited in scope and comprehensive-
ness [17], limiting the planning of prevention interven-
tions and monitoring their effectiveness to control these
infections. We determined for the first time prevalence
estimates of serologic markers of HCV, HBV, HAV,
HIV and HSV-2 and assessed variations across sociode-
mographic and behavioral characteristics in the adult
population of Puerto Rico.
Methods
Study Design and Sampling Procedures
Detailed descriptions of the survey design and recruit-
ment have been published elsewhere [18,19]. Briefly, a
seroepidemiologic survey was designed using a stratified,
multistage, probability cluster sample of all households
in Puerto Rico. To define the sampling frame, Puerto
Rico was stratified on the basis of AIDS incidence rates
among injecting drug users (IDUs) and adult population
density. The configuration of the sample strata assumed
that HCV seroprevalence would vary systematically
across the four strata and that prevalence estimates
would gain precision. Four strata were derived corre-
sponding to municipalities with above and at or below
median AIDS incidence rates among IDUs (9.9/100,000
population reported in Puerto Rico in 2002) and above
and at or below median population density (486 per
square mile). Statistics provided by the Puerto Rico
AIDS Surveillance System [20] were used to determine
the incidence rate of AIDS among IDUs in each munici-
pality in Puerto Rico during 2002. An estimated sample
size of 2,000 adults randomly selected among strata of
equal sizes was calculated on the basis of an expected
prevalence of HCV infection of 6.3%, 95% confidence
level and precision level of 3% [17,21]. Due to the com-
plex sampling design, the prevalence estimation was
weighted according to the inverse of probability of selec-
tion and participation rate in each selected block. The
probability of selection was defined as a function of the
geographic strata, households’ blocks, and sex distribu-
tion according to post-censal estimates in Puerto Rico.
Household individuals within each stratum were
selected in four stages. In the first stage, census blocks
were sorted by median age and median housing value to
achieve adequate representation of disease burden across
all age groups and socioeconomic levels, and a systema-
tic random selection was made with probability propor-
tional to the number of households. The second
selection stage consisted of a random selection of one
block within each census block group. In a third stage,
one segment of approximately 25 consecutive house-
holds was randomly selected from each block. A total of
108 segments were selected comprising 3,487 occupied
households. Enumerators were able to contact residents
in 3,386 households (97.1%), and 2,123 of these house-
holds had at least one adult aged 21 to 64 years old. In
the final stage, one eligible adult was randomly selected
from each household and invited to participate in the
study.
Participants were given an appointment to visit a
mobile examination unit located in the vicinity of their
homes. At the mobile examination unit, a formal
informed consent procedure was conducted which pro-
vided participants with information of all study proce-
dures. Upon formally consenting, participants were
offered pretest counseling. Participants completed a face-
to-face interview and then were asked to complete a self-
administered questionnaire using an ACASI system
implemented using QDS (Nova Research Co., Washing-
ton, D.C.). After interviewing, a certified phlebotomist
Pérez et al. BMC Infectious Diseases 2010, 10:76
http://www.biomedcentral.com/1471-2334/10/76
Page 2 of 11collected blood specimens of 15-ml for HAV, HBV,
HCV, HIV, and HSV-2 testing. Participants received a
$50.00 financial compensation upon completion of the
study procedures for their time effort in addition to edu-
cational materials on prevention of blood-borne infec-
tions, STIs and enteric infections. Participants, whose
test results were positive, received post-counseling and
referrals for follow-up medical evaluation. Field work was
conducted between June 2005 and February 2008. All
human subjects provided informed consent for this study
under a protocol (number #A0420105) approved by the
University of Puerto Rico Medical Sciences Campus insti-
tutional review board.
Measures
Face-to-face interviews covered standard sociodemo-
graphic characteristics plus extensive information on
medical diagnoses including other STIs (self-reported
syphilis, gonorrhea, genital warts, and infection with
genital Chlamydia trachomatis), tattooing and body
piercing practices, knowledge on viral infections under
study, and self-reports of HAV and HBV vaccination
coverage. The ACASI system ascertained cigarette and
alcohol use, lifetime and recent drug use, sex-related
risk behaviors, and history of incarceration. Trained
interviewers conducted the personal interview and were
available to answer questions during the self-adminis-
tered interview.
Laboratory Analyses
Testing for antibody to HCV was performed with a che-
miluminiscent immunoassay (ADVIA Centaur®, Siemens
Healthcare Diagnostics, Deerfield, IL) and confirmation
by recombinant immunoblot assay (Laboratory Corpora-
tion of America® Holdings, Tampa, FL). HBV antibodies
were assayed with a chemiluminiscent immunoassay
(IMMULITE® 2000, Siemens Healthcare Diagnostics,
Los Angeles, CA) for total hepatitis B core antibody
(anti-HBc), hepatitis B surface antigen (HBsAg) and
hepatitis B surface antibody (anti-HBs). HBV serologic
testing results were classified as follows: past or present
infection (HbsAg negative, anti-HBc positive and anti-
HBs positive; HBsAg positive, anti-HBc positive and
anti-HBs negative) and serologic evidence of vaccination
(anti-HBs positive, HBsAg negative and anti-HBc nega-
tive). Total HAV antibodies were measured by a chemi-
luminiscent immunoassay (ADVIA Centaur®,S i e m e n s
Healthcare Diagnostics, Deerfield, IL). HIV-1 antibodies
were assayed with commercial enzyme immunoassay
(Evolis™ Bio-Rad Laboratories, Inc., Hercules, CA) and
confirmed by Western blot (Laboratory Corporation of
America® Holdings, Tampa, FL). HSV-2 type-specific
IgG was tested via enzyme immunoassay (Laboratory
Corporation of America® Holdings, Tampa, FL).
Statistical Analysis
Prevalence estimates of viral hepatitis (HAV, HBV,
HCV), HIV and HSV-2 were estimated using logistic
regression models weighting for the probability of partici-
pation in each household block and the inverse of the
probability of selection according to the geographic
strata, households’ blocks, and sex distribution in Puerto
Rico. To account for the correlation between subjects
selected from the same block segment, the parameters of
this model were estimated using a generalized estimating
equations approach [22]. Population estimates were gen-
erated by multiplying population counts obtained from
the postcensal estimates of the civilian, noninstitutiona-
lized population aged 21-64 years as of July 1, 2008 by
the weighted prevalence estimate and rounded to the
nearest thousand [23]. Data management and statistical
analyses were performed using the statistical package
Stata (Version 10.0, College Station, TX, USA).
Results
Characteristics of Study Population
Of the selected residents, 1,654 (77.9%) consented to
participate in the face-to-face interview and provided
blood samples suitable for antibody testing for viral
infections. The age distribution of study participants
(21-29 years: 22.2%; 30-39 years: 24.2%; 40-49 years:
26.3%; 50-64 years: 27.3%) was similar to that of the
adult population of Puerto Rico according to the Census
2000 [24] (Table 1). Females were slightly overrepre-
sented in that they made up 56.4% of the study sample.
Nearly 75% reported to have completed high school,
66.2% were living below the poverty level (annual family
income below $20,000), and 10.5% did not have health
care coverage at the time of the interview. More than
half (51.3%) reported first sexual intercourse before age
18, 58% reported 2-9 lifetime sexual partners, and 6.1%
of men had a history of sexual contact with same-sex
partners. Over one-third (35.5%) of participants reported
lifetime non-injection drug use, whereas 1.5% reported
injection drug use. Marijuana (29.3%), cocaine (14.9%),
and heroin (6.5%) were the most commonly used drugs.
Nearly 15% informed tattooing practices, 30.1% had a
history of ear or other body piercing, 4.8% reported
receipt of blood transfusions prior to 1992, 5.2% had a
history of other STIs, and 8.2% had a history of impri-
sonment. Self-reported vaccination coverage for HAV,
defined as having received two doses of the vaccine, was
indicated by only 1.6% of participants, whereas 13.2%
had serologic evidence of hepatitis B vaccination.
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HCV
Weighted prevalence was 2.3% (95% CI: 1.3% - 4.2%),
corresponding to 53,000 (95% CI: 30,000 - 95,000) HCV
antibody-positive persons in Puerto Rico (Table 2). This
prevalence increased to 2.7% in strata 3 and 4, munici-
palities with a high incidence of AIDS among injecting
drug users. Most of these individuals (80%) were una-
ware of their HCV serostatus (data not shown).
Although the peak in age-specific prevalence was
observed among people aged 40-49 years (2.7%) and was
lowest among those aged 50-64 years (1.3%), variations
across age groups were not statistically significant
(Table 3). Anti-HCV prevalence was significantly higher
in men (4.0%) and those with public (4.1%) or no health
insurance (2.9%) (p < 0.01 and p < 0.001, respectively).
Prevalence did not vary according to education and
annual family income. When high risk behaviors were
examined, anti-HCV prevalence was significantly (p <
0.001) higher for those who had first sex before the age
of 12 years (10.2%) and among persons reporting at
least 10 lifetime sexual partners (5.5%) but not among
men who had sex with men. Anti-HCV prevalence was
significantly (p < 0.001) higher among persons who had
ever injected drugs (76.1%) compared to those who
h a de v e ru s e dn o n - i n j e c t i o nd r u g s( 1 . 8 % )o rt h o s ew h o
had never used drugs (0.6%). Anti-HCV was also signifi-
cantly (p < 0.05) correlated with a history of tattooing
practice (10.2%), body piercing (4.0%), receipt of blood
transfusions before 1992 (6.3%), history of imprisonment
(17.5%) but not with a history of other STIs. Positivity
to HBV (17.4%) and HSV-2 (5.1%) antibody testing were
significantly (p < 0.01) associated to HCV seropositivity
(Table 4).
Table 1 Demographic and risk-related characteristics of
1,654 adults aged 21-64 in Puerto Rico, 2005-2008
Characteristics Number
a Percent (%)
Age in years
21-29 367 22.2
30-39 400 24.2
40-49 435 26.3
50-64 452 27.3
Sex
Female 933 56.4
Male 721 43.6
Years of education
≥ 12 1237 74.8
< 12 417 25.2
Annual family income
≥ 20,000 515 33.8
< $20,000 1011 66.2
Health care coverage
Private 746 45.1
Public 735 44.4
None 173 10.5
Age in years at first sexual intercourse
< 12 42 2.6
12-17 762 48.7
≥ 18 762 48.7
Number of lifetime sexual partners
0-1 336 21.9
2-9 890 58.0
≥ 10 308 20.1
Men who have sex with men
Never 633 93.9
Ever 41 6.1
Lifetime drug use
None 1042 63.0
Non-IDU 587 35.5
IDU 25 1.5
Type of substance use
b
Marijuana 484 29.3
Cocaine 246 14.9
Heroin 108 6.5
Tattooing practice
Never 1409 85.2
Ever 244 14.8
Body piercing
Never 1154 69.9
Ever 498 30.1
Blood transfusions prior to 1992
Never 1574 95.2
Ever 80 4.8
History of other STIs
c
No 1568 94.8
Yes 86 5.2
Table 1: Demographic and risk-related characteristics of
1,654 adults aged 21-64 in Puerto Rico, 2005-2008
(Continued)
History of imprisonment
Never 1518 91.8
Ever 136 8.2
Self-reported HAV vaccination coverage
No 1628 98.4
Yes 26 1.6
Serologic evidence of HBV vaccination
No 1435 86.8
Yes 219 13.2
aTotal may not equal the overall sample size because of non-response.
bCategories of substance use are not mutually exclusive.
cSelf-reported history of syphilis, gonorrhea, genital warts, and chlamydia
infection.
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Weighted prevalence of past or present infection with
HBV was 3.1% (95% CI: 2.0% - 4.7%), equating to
71,000 (95% CI: 47,000 - 108,000) adults with past or
present HBV infection in Puerto Rico (Table 2). Preva-
lence of past or present infection with HBV was similar
across strata. The majority of HBV seropositive indivi-
duals (98.3%) were unaware of their serostatus (data not
shown). Prevalence of past or present HBV infection
increased significantly (p < 0.05) with age, reaching 5.4%
among individuals aged 50-64 years (Table 3). Although
prevalence was higher in males (4.3%) and among those
with public (4.5%) or no health insurance (3.4%), the dif-
ferences were marginally significant (p = 0.07 and
p = 0.097, respectively). Prevalence was significantly
(p < 0.05) higher in those with less than 12 years of
education (5.7%), those living below the poverty level
(4.0%), those who had first sex before the age of 12
years (15.2%), persons who had ever injected drugs
(23.5%), and those with a history of receiving blood
transfusions before 1992 (11.6%) and imprisonment
(11.2%). People with positive antibody testing results for
HCV (27.1%), HAV (5.7%) and HSV-2 (6.2%) had signif-
icantly (p < 0.01) higher HBV seroprevalence than those
with negative results (Table 4).
HAV
Weighted prevalence of anti-HAV was 41.3% (95% CI:
36.9% - 45.8%), and the estimated number of adults ever
infected with HAV in Puerto Rico was 933,000 (95% CI:
834,000 - 1,035,000) (Table 2). No marked variations in
HAV seroprevalence were observed across strata. Most
of HAV seropositive individuals (96.4%) were unaware
of their serostatus (data not shown). Prevalence of anti-
HAV increased steeply (p < 0.001) with age, from 8.2%
in persons aged 21-29 years to 89.0% in those aged 50-
64 years (Table 3). Similarly, prevalence was significantly
(p < 0.001) higher in people who had less than 12 years
of education (59.3%) and lower annual family income
(45.9%). Moreover, anti-HAV prevalence was higher
(p < 0.01) among those who reported either one or no
sexual partner (50.9%), injection drug use (66.9%), no
history of tattooing or body piercing practices (43.7%
Table 2 Weighted seroprevalence (%) of selected viral infections among adults 21-64 years: Puerto Rico, 2005-2008
Weighted prevalence of antibodies Estimated number of adults infected in Puerto Rico
a
Prevalence 95% CI Number 95% CI
HCV (n = 1,650) 2.3 1.3 - 4.2 53000 30000 - 95000
Stratum 1
b 2.1 1.1 - 4.1 9000 5000 - 17000
Stratum 2
c 0.5 0.1 - 2.1 3000 1000 - 10000
Stratum 3
d 2.7 1.6 - 4.8 8000 5000 - 13000
Stratum 4
e 2.7 1.5 - 4.7 30000 17000 - 52000
HBV (n = 1,654) 3.1 2.0 - 4.7 71000 47000 - 108000
Stratum 1
b 5.3 3.6 - 7.8 23000 15000 - 33000
Stratum 2
c 2.6 1.4 - 4.6 12000 7000 - 22000
Stratum 3
d 2.8 1.5 - 5.1 8000 5000 - 14000
Stratum 4
e 2.9 1.7 - 5.0 33000 19000 - 56000
HAV (n = 1,650) 41.3 36.9 - 45.8 933000 834000 - 1035000
Stratum 1
b 42.5 37.9 - 47.3 178000 159000 - 198000
Stratum 2
c 38.5 33.9 - 43.3 180000 158000 - 202000
Stratum 3
d 42.4 37.6 - 47.4 113000 100000 - 126000
Stratum 4
e 42.0 37.2 - 46.8 465000 413000 - 520000
HIV (n = 1,650) 1.1 0.5 - 2.3 25000 12000 - 51000
Stratum 1
b 0.2 0.03 - 1.4 1000 1000 - 6000
Stratum 2
c 0.2 0.03 - 1.6 2000 1000 - 8000
Stratum 3
d 0.7 0.2 - 2.1 2000 1000 - 6000
Stratum 4
e 1.3 0.6 - 3.0 15000 7000 - 34000
HSV-2 (n = 1,446) 22.3 18.5 - 26.7 505000 418000 - 603000
Stratum 1
b 19.7 16.0 - 24.1 83000 67000 - 101000
Stratum 2
c 22.0 18.1 - 26.5 103000 85000 - 124000
Stratum 3
d 24.9 20.5 - 29.8 66000 55000 - 80000
Stratum 4
e 22.1 18.1 - 26.7 246000 201000 - 297000
aEstimated numbers and their associated 95% CI are rounded to the nearest thousand.
bStrata 1 include municipalities with low AIDS incidence rates among IDUs and low population density.
cStrata 2 include municipalities with low AIDS incidence
rates among IDUs and high population density.
dStrata 3 include municipalities with high AIDS incidence rates among IDUs and low population density.
eStrata 4
include municipalities with high AIDS incidence rates among IDUs and high population density.
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Puerto Rico, 2005-2008.
Characteristics Prevalence (%) (95% CI)
Anti-HCV Anti-HBV Anti-HAV Anti-HIV Anti-HSV-2
Age in years
21-29 2.3 (0.8 - 6.6) 1.2 (0.4 - 3.3)
a 8.2 (5.1 - 12.7)
c *
b, d 14.8 (10.5 - 20.3)
c
30-39 2.5 (1.2 - 4.9) 2.7 (1.3 - 5.4) 13.9 (9.9 - 19.2) 1.0 (0.3 - 3.5) 15.5 (10.7 - 21.8)
40-49 2.7 (1.3 - 5.4) 3.6 (2.1 - 6.2) 49.4 (41.7 - 57.2) 1.7 (0.6 - 4.7) 29.1 (24.2 - 34.5)
50-64 1.3 (0.4 - 4.4) 5.4 (3.3 - 8.6) 89.0 (84.6 - 92.2) 0.7 (0.2 - 2.0) 29.0 (23.3 - 35.4)
Sex
Female 1.0 (0.4 - 2.1)
b 2.5 (1.6 - 3.9) 41.3 (36.7 - 46.0) 0.8 (0.3 - 2.0) 25.6 (21.5 - 30.2)
b
Male 4.0 (2.3 - 6.8) 4.3 (2.7 - 6.8) 41.5 (36.7 - 46.5) 1.0 (0.4 - 2.4) 17.8 (14.3 - 22.1)
Years of education
≥ 12 2.2 (1.3 - 3.6) 2.5 (1.7 - 3.9)
a 35.8 (32.3 - 39.4)
c 0.6 (0.2 - 1.5) 20.2 (17.2 - 23.5)
b
< 12 2.3 (1.0 - 5.3) 5.7 (3.7 - 8.6) 59.3 (54.5 - 63.9) 1.7 (0.7 - 4.3) 29.3 (22.8 - 36.8)
Annual family income
≥ $20,000 1.4 (0.4 - 4.4) 1.1 (0.5 - 2.6)
b 32.9 (28.6 - 37.5)
c 1.1 (0.4 - 3.4) 16.9 (12.8 - 21.9)
b
< $20,000 2.3 (1.3 - 4.0) 4.0 (2.9 - 5.6) 45.9 (41.8 - 50.1) 0.6 (0.2 - 1.6) 25.9 (21.8 - 30.5)
Health care coverage
Private 0.4 (0.2 - 0.9)
c 2.2 (1.3 - 3.7) 43.8 (38.9 - 48.9) 0.8 (0.2 - 2.3) 17.3 (14.0 - 21.3)
c
Public 4.1 (2.4 - 6.9) 4.5 (3.0 - 6.7) 40.6 (36.0 - 45.3) 0.8 (0.3 - 1.9) 27.6 (23.0 - 32.6)
None 2.9 (0.8 - 9.6) 3.4 (1.4 - 8.2) 33.9 (24.2 - 45.1) 1.6 (0.3 - 7.8) 24.0 (16.5 - 33.6)
Age at first sexual intercourse
< 12 10.2 (3.3 - 27.2)
c 15.2 (5.7 - 34.5)
b 57.2 (38.8 - 73.8) 2.0 (0.5 - 8.4) 33.1 (18.7 - 51.6)
12-17 3.6 (2.0 - 6.1) 3.7 (2.4 - 5.7) 38.3 (33.9 - 42.9) 0.9 (0.4 - 2.3) 23.9 (19.4 - 29.2)
≥ 18 0.5 (0.2 - 1.1) 1.9 (1.1 - 3.3) 43.2 (38.9 - 47.6) 0.3 (0.1 - 1.6) 20.1 (16.4 - 24.4)
Number of lifetime sexual partners
0-1 0.7 (0.1 - 3.3)
c 1.9 (0.9 - 4.0) 50.9 (44.3 - 57.6)
b *
d 11.5 (7.9 - 16.5)
c
2-9 1.2 (0.6 - 2.6) 2.7 (1.8 - 4.2) 37.4 (33.5 - 41.4) 0.9 (0.4 - 2.3) 24.1 (20.1 - 28.6)
≥ 10 5.5 (3.0 - 9.8) 4.6 (2.6 - 8.0) 41.5 (33.2 - 50.3) 0.7 (0.2 - 1.9) 25.1 (19.9 - 31.1)
Men who have sex with men
Never 4.0 (2.3 - 6.9) 4.3 (2.6 - 7.1) 41.2 (36.3 - 46.2) 0.3 (0.1 - 0.9)
c 16.8 (12.9 - 21.5)
Ever 2.6 (0.7 - 9.3) 3.1 (0.7 - 13.0) 49.9 (31.9 - 67.9) 7.3 (1.9 - 24.5) 22.0 (11.5 - 38.1)
Lifetime drug use
None 0.6 (0.2 - 1.6)
c 2.6 (1.7 - 3.9)
c 47.7 (44.1 - 51.4)
c 0.7 (0.3 - 1.9) 20.3 (16.6 - 24.5)
Non-IDU 1.8 (0.9 - 3.5) 3.5 (2.1 - 5.8) 29.3 (24.3 - 34.9) 1.0 (0.4 - 2.8) 25.4 (20.9 - 30.6)
IDU 76.1 (55.2 - 89.1) 23.5 (8.8 - 49.3) 66.9 (42.9 - 84.5) 2.8 (0.6 - 12.4) 31.9 (10.3 - 65.5)
Tattooing practice
Never 0.9 (0.5 - 1.6)
c 2.9 (2.0 - 4.0) 43.7 (40.4 - 47.0)
c 0.6 (0.3 - 1.4) 21.8 (18.2 - 25.8)
Ever 10.2 (6.0 - 16.8) 5.6 (2.8 - 11.1) 27.5 (21.4 - 34.6) 2.2 (0.6 - 7.1) 26.2 (19.8 - 33.9)
Body piercing
Never 1.4 (0.8 - 2.6)
a 3.6 (2.5 - 5.1) 48.9 (45.2 - 52.7)
c 1.0 (0.5 - 2.2) 23.0 (20.0 - 26.4)
Ever 4.0 (2.1 - 7.5) 2.7 (1.3 - 5.6) 24.4 (19.9 - 29.6) 0.5 (0.1 - 2.1) 21.0 (15.8 - 27.5)
Blood transfusions prior to 1992
Never 2.0 (1.2 - 3.2)
b 2.9 (2.1 - 4.0)
b 40.1 (37.1 - 43.3)
c 0.4 (0.2 - 1.0)
c 21.9 (18.6 - 25.6)
Ever 6.3 (2.5 - 14.6) 11.6 (5.3 - 23.6) 65.2 (52.7 - 75.8) 9.2 (3.4 - 22.8) 31.2 (19.6 - 45.7)
History of other STIs
e
Yes 2.7 (0.7 - 9.1) 4.9 (2.2 - 10.7) 47.3 (35.0 - 59.8) 5.9 (1.9 - 16.5)
b 33.9 (22.7 - 47.3)
a
No 2.2 (1.3 - 3.6) 3.2 (2.3 - 4.5) 41.1 (37.9 - 44.3) 0.6 (0.3 - 1.4) 21.9 (18.6 - 25.6)
History of imprisonment
Never 0.8 (0.4 - 1.5)
c 2.6 (1.8 - 3.7)
b 41.2 (37.8 - 44.7) 0.6 (0.2 - 1.3)
b 21.1 (18.1 - 24.5)
b
Ever 17.5 (11.4 - 26.1) 11.2 (5.4 - 21.7) 43.0 (33.5 - 53.0) 4.1 (1.4 - 10.9) 36.0 (25.4 - 48.0)
aP<0 . 0 5 ;
bP < 0.01;
cP < 0.001.
dIndicates a relative standard error of 30% or more, thus this reflects a potentially unreliable estimate and is not shown.
eSelf-reported history of syphilis, gonorrhea, genital warts, and chlamydia infection.
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sions prior to 1992 (65.2%). Individuals with positive
results on HBV (71.5%) and HSV-2 (53.7%) antibody
testing had significantly (p < 0.001) higher seropreva-
lence of HAV than seronegative individuals (Table 4).
HIV
Weighted prevalence was 1.1% (95% CI: 0.5% - 2.3%),
corresponding to 25,000 (95% CI: 12,000 - 51,000) per-
sons ever infected with HIV in the adult population of
Puerto Rico (Table 2). This prevalence reached 1.3% in
stratum 4 (municipalities with a high population density
and high AIDS incidence rate among IDUs). The per-
centage of HIV seropositive individuals who were una-
ware of their status was 36.4% (data not shown).
Prevalence of HIV was significantly (p < 0.05) higher in
adults aged 40-49 years (1.7%), men who had sex with
men (7.3%), those who reported receipt of blood trans-
fusions prior to 1992 (9.2%), and individuals with a his-
tory of other STIs (5.9%) and imprisonment (4.1%)
(Table 3). Adults who were seropositive to HSV-2 had a
significantly higher prevalence of HIV antibodies than
those who were seronegative (3.0% vs. 0.1%, p < 0.001)
(Table 4).
HSV-2
Weighted prevalence was 22.3% (95% CI: 18.5% -
26.7%), equating to 505,000 (95% CI: 418,000 - 603,000)
seropositive individuals to HSV-2 in the adult popula-
tion of Puerto Rico (Table 2). Most of these individuals
(97.8%) were unaware of their HSV-2 serostatus (data
not shown). Seroprevalence was significantly (p < 0.01)
higher among adults aged 40-49 and 50-64 years (29.1%
and 29.0%, respectively) and females (25.6%) (Table 3).
Prevalence was also significantly (p < 0.01) higher
among those who had less than 12 years of education
(29.3%), lived below the poverty level (25.9%), and were
covered by public health insurance or were uninsured
(27.6% and 24.0%, respectively). HSV-2 seropositivity
significantly (p < 0.001) increased with the lifetime num-
ber of sexual partners, from 11.5% for one partner or
less to 25.1% for those with at least 10 sexual partners.
Individuals who reported a history of other STIs and
those with a history of imprisonment were also signifi-
cantly more likely to be HSV-2 seropositive than those
without such histories (33.9% vs. 21.9%, p < 0.05; 36.0%
vs. 21.1%, p < 0.01; respectively). People with positive
results for anti-HCV (55.4%), anti-HBV (39.9%), anti-
HAV (29.4%), and anti-HIV (89.3%) had significantly
(p < 0.01) higher seroprevalence of HSV-2 compared to
those with negative results (Table 4).
Discussion
To our knowledge, this is the first population-based sur-
vey that provides nationally representative estimates of
the seroprevalence of viral hepatitis, HIV and HSV-2 in
the non-institutionalized adult population of Puerto
Rico, vital information that provides insight into disease
burden and opportunities for prevention. Seroprevalence
estimates for HCV (2.3%), HBV (3.1%), and HSV-2
(22.3%) in Puerto Rico are roughly in agreement with
estimates obtained in the US population aged 20-59
years, where age-adjusted prevalence was 2.4% for HCV
(1.6% in the most recent NHANES), 5.6% for HBV, and
25.1% for HSV-2 [9-12]. However, HIV and HAV sero-
prevalence estimates in Puerto Rico (1.1% and 41.3%,
Table 4 Prevalence of concomitant antibodies to viral hepatitis, HIV and HSV-2, Puerto Rico, 2005-2008.
Prevalence (%) (95% CI)
Characteristic Anti-HCV Anti-HBV Anti-HAV Anti-HIV Anti-HSV-2
Antibody to HCV
Positive – 27.1 (13.9 - 46.0)
a 61.2 (34.5 - 82.5) 2.2 (0.5 - 8.6) 55.4 (30.9 - 77.6)
b
Negative – 2.7 (2.0 - 3.8) 40.9 (37.8 - 44.1) 0.8 (0.4 - 1.6) 21.7 (18.5 - 25.3)
Antibody to HBV
Positive 17.4 (8.5 - 32.3)
a – 71.5 (56.7 - 82.7)
a – 39.9 (27.5 - 53.7)
b
Negative 1.7 (1.0 - 2.8) – 40.3 (37.1 - 43.6) – 21.7 (18.6 - 25.3)
Antibody to HAV
Positive 3.3 (1.8 - 6.1) 5.7 (3.9 - 8.3)
a – 1.4 (0.6 - 3.0) 29.4 (24.8 - 34.5)
a
Negative 1.4 (0.6 - 3.2) 1.6 (1.0 - 2.7) – 0.5 (0.1 - 1.7) 17.6 (14.2 - 21.5)
Antibody to HIV
Positive 5.2 (1.0 - 23.0) – 66.2 (29.5 - 90.1) – 89.3 (57.0 - 98.1)
a
Negative 2.2 (1.3 - 3.5) – 41.1 (37.9 - 44.4) – 21.9 (18.7 - 25.4)
Antibody to HSV-2
Positive 5.1 (2.5 - 10.1)
b 6.2 (3.9 - 9.8)
b 53.7 (46.5 - 60.8)
a 3.0 (1.2 - 6.9)
a –
Negative 1.2 (0.6 - 2.3) 2.7 (1.8 - 3.9) 36.9 (33.9 - 40.0) 0.1 (0.02 - 0.4) –
–, Not applicable.
aP<0 . 0 0 1 ;
bP < 0.01.
Pérez et al. BMC Infectious Diseases 2010, 10:76
http://www.biomedcentral.com/1471-2334/10/76
Page 7 of 11respectively) were higher than the corresponding figures
for the US adult population (0.5% and 30.7%, respec-
tively) [13,14]. The higher HIV seroprevalence found in
this study is consistent with national surveillance data
showing that Puerto Rico has one of the highest overall
rates of HIV/AIDS among states and territories of the
US, mainly attributed to sharing of contaminated inject-
ing equipment [15,16]. The higher HAV seroprevalence
might be attributed to poorer economic development,
sanitation, and environmental conditions in Puerto Rico
[13,25]. However, prevalence estimates for viral hepati-
tis, HIV and HSV-2 in these studies are probably under-
estimated because the sampling frame excluded
subpopulations at high risk of these infections including
the homeless and incarcerated individuals [26,27].
The vast majority of individuals first learned of their
viral hepatitis and HSV-2 serostatus from this survey.
These findings parallel results from other studies that
have consistently found that a large percentage of
the population is not aware of their serostatus due to
the asymptomatic nature of these infections [11,28]. The
percentage of people unaware of their HIV seropositivity
(36%), although substantially lower than for the other
viral infections under study, is higher than the estimate
in the US, where approximately 21% of HIV-positive
persons remain undiagnosed [29]. This finding calls for
a multisectoral approach to the HIV/AIDS epidemic in
Puerto Rico to improve counseling, testing, and linkage
to appropriate care and treatment services among high-
risk individuals. In addition, widespread implementation
of prevention interventions with proven efficacy could
further prevent transmission of HIV [30]. Taking into
consideration that the prevalence of antibodies to HCV,
HBV and HSV-2 were considerably higher than the pre-
valence of HIV, the need for effective approaches for
the prevention and control of viral hepatitis and other
STIs is underscored. To increase knowledge and aware-
ness of these infections among health care providers, at-
risk populations and the public, integration of HCV,
HBV and HSV-2 counseling and screening into HIV
existing prevention services and outreach through social,
sexual and drug-using networks might represent a valu-
able approach to reach high-risk individuals [31].
Dramatic variations in the prevalence of antibodies to
viral hepatitis, HIV and HSV-2 were observed according
to demographic and behavioral factors. As expected,
anti-HAV increased markedly with age, primarily
reflecting infection in the older cohorts that were
acquired during childhood [13,25]. Antibodies to both
HBV and HSV-2 also increased with age, findings con-
sistent with reports from different geographic areas
[10,12,32]. HIV seroprevalence increased to a peak of
1.7% in those aged 40-49 years and decreased to 0.7% in
those aged 50-64 years. These observations are also
consistent with HIV surveillance data in Puerto Rico
where the majority of new infections in 2006 occurred
among persons aged 30-49 years [16].
Significant sex differences were found for seropreva-
lence of HCV and HSV-2. Men were four times more
likely to be anti-HCV positive, a finding that is in agree-
ment with several population-based surveys, possibly
reflecting riskier drug behaviors in males [11,33]. On
the other hand, prevalence of HSV-2 antibodies was sig-
nificantly higher among women. An extensive review of
the prevalence of HSV-2 serum antibodies for different
populations worldwide documents a higher prevalence
among women [31]. Potential explanations for this find-
ing include the higher efficiency of HSV-2 transmission
from men to women as compared with that from
women to men and differences between women and
men in sexual behaviors [10,31].
Prevalence of antibodies to viral hepatitis and HSV-2
was significantly higher in those with lower socioeco-
nomic status in Puerto Rico, defined as having less than
a high school education, living below the poverty level
or having a public or no health insurance. Epidemiologic
studies worldwide have shown an inverse association
between HAV seropositivity and socioeconomic indica-
tors, particularly in developing countries [13,25]. Simi-
larly, studies show socioeconomic status, poverty and
geography to be major determinants of STIs disparities
[5,6].
In general, prevalence of viral infections was higher
among higher risk sexual behavior groups. Although
efficiency of sexual transmission of HCV appears to be
relatively low, the dose-response relationships observed
between prevalence of anti-HCV and age at first sexual
relation and number of lifetime sexual partners is in
agreement with other studies [2,11,17]. Recent surveil-
l a n c ed a t af o ra c u t ev i r a lh e p a t i t i si nt h eU Sd u r i n g
2007 found that 42% of cases reported having multiple
sex partners, 10% reported having sexual contact with
another known HCV infected person, and 10% were
men who had sex with men [2]. Prevalence of past or
present HBV infection was higher for individuals who
had their first sexual intercourse before the age of 12
years than among those whose first sex was later in life.
HSV-2 seroprevalence for adults who reported having
had at least two sexual partners was more than twice
t h es e r o p r e v a l e n c ef o rt h o s ew h or e p o r t e do n l yo n eo r
no sexual partner in their lifetime. HIV seropositivity
was significantly higher in men who ever reported sex
with other men than in men who did not report same-
sex contact. These observations are consistent with
surveillance findings and previous seroepidemiologic
surveys and support the notion that adoption of HIV
and other STIs’ risk reduction behaviors should be
encouraged for the general population, especially those
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risk for exposure to these viral agents [10,12,14,28,32].
There is ample evidence showing that injection drug
use is the single most important risk factor for HCV
infection. In this study, prevalence of anti-HCV was 76%
among those who reported lifetime injection drug use.
In addition, prevalence of HCV antibodies among those
who reported lifetime non-injection drug use was three-
fold higher than those who reported no drug use. Preva-
lence of anti-HCV among IDU was higher than the
reported figure in the NHANES 1999-2002 (57.5%) and
in the US surveillance system for acute viral hepatitis
during 1998-2007 (average: 44%; range: 38%-54%)
[2,11,17]. Injection drug use was also common among
HBV and HAV seropositive individuals, findings consis-
tent with surveillance data for acute viral hepatitis in the
US during 2007 [2].
Several infectious diseases have been found to be asso-
ciated with a history of cosmetic procedures, such as
tattooing and body piercing [34,35]. In our study, indivi-
duals with a history of tattooing and body piercing prac-
tices had a higher HCV seroprevalence than those
without such practices. Similarly, adults who reported a
history of imprisonment were also more likely to be ser-
opositive to HCV, HBV, HIV and HSV-2. These findings
support the implementation of a comprehensive
approach to prevent these infections in the correctional
setting [36]. Further investigation is also required to
determine if these types of exposures contribute to the
transmission of blood borne pathogens in the general
population.
The Centers for Disease Control and Prevention have
estimated that blood transfusions might have been the
source of HCV infection for nearly 7% of cases [2]. In
our study, 6.3% of adults who had a history of receiving
blood transfusions prior to 1992 were three-fold more
likely to be HCV seropositive than individuals without
such a history. Similarly, individuals who reported
receipt of blood transfusions also had a higher preva-
lence of antibodies for HBV and HIV, possibly reflecting
the high risk of acquiring these infections via transfused
blood products prior to the introduction of more sensi-
tive screening techniques to improve blood supply safety
or from units donated during the antibody-negative win-
dow period before seroconversion [37].
A higher seroprevalence of HIV and HSV-2 was
observed among adults who self-reported a history of
other STIs including syphilis, gonorrhea, genital warts,
and chlamydia infection. These findings are in agree-
ment with seroprevalence surveys and surveillance data
in the US, that show that the two most commonly
reported STIs in the US, chlamydia and gonorrhea,
along with syphilis and herpes, have been associated
with an increased transmission of HIV [3,5-7].
Moreover, numerous observational studies suggest that
genital herpes is associated with an increased risk of
HIV acquisition and may account for 40% to 60% of
new HIV infections in high HSV-2 prevalence popula-
tions [32,38]. When concomitant antibodies to viral
infections under study were examined, individuals who
were HSV-2 seropositive had a significantly higher pre-
valence of antibodies to HCV, HBV, HAV and HIV.
Similarly, HBV seropositive individuals had a higher pre-
valence of antibodies to HCV and HAV. These findings
support the view that viral hepatitis and STIs share
similar at-risk populations and social determinants
[5,7,8]. Continued efforts to prevent new infections in
high risk groups are essential, along with expansion of
target HAV and HBV vaccination programs, screening
strategies for viral hepatitis and STIs, and preventive
activities to reduce the progression in people with
chronic hepatitis.
Strengths of our study are the inclusion of a probabilis-
tic sample of adults which enhances the generalizability
of the findings in Puerto Rico, an adequate response rate
(78%), and extensive data regarding risk factors. This
study also demonstrated the feasibility of conducting a
household survey that combined face-to-face interviews,
ACASI, and biochemical measurements in a mobile
examination unit in Puerto Rico, a methodology similar
to that used in the NHANES program. However, there
are several limitations to be considered when interpreting
the results of this study. Although the distribution of age,
education level, and family income of our sample was
comparable to that of the adult population of Puerto
Rico, according to the US Census 2000 [24], females
were overrepresented. However, prevalence of the viral
infections under study was not affected when the corre-
sponding proportions of males and females in Puerto
Rico from the Census 2000 were considered. Second, the
small number of HIV positive individuals limited our
ability to make reliable prevalence estimates according to
sociodemographic and behavioral characteristics. Third,
prevalence of anti-HCV and anti-HBV does not distin-
guish between recent or remote infection, so these esti-
mates do not shed light on the current burden of chronic
viral hepatitis. Finally, other well-known risk factors for
HCV infection, such as long-term hemodialysis, history
of organ transplantation, and health care work involving
frequent exposure to blood, were not evaluated because
of their low frequency. However, CDC estimates that
these risk factors generally account for fewer than 10% of
HCV infections [2].
Notwithstanding these limitations, this study repre-
sents a further step toward a true understanding of the
burden of these viral infections in Puerto Rico. Preven-
tion and control of these infections is challenging given
their asymptomatic nature. Immunization strategies
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and HAV infections. However, there are currently no
licensed vaccines to prevent the acquisition of HCV,
HIV and HSV-2, thus, prevention of these infections
mostly depends on preventing high-risk injecting and
sexual behaviors.
Conclusions
This study sheds light on the epidemiology of viral
hepatitis, HIV and HSV-2 infections and underscores
their disproportionate impact among specific population
subgroups in Puerto Rico. Further research and policy
development are urgently needed to strengthen viral
hepatitis and STIs prevention and control strategies,
improve surveillance of these infections, and provide
integrated health services to ensure appropriate counsel-
ing, testing, and medical management of infected
persons.
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